Marshall Wace’s Greenwich LifeSciences GLSI Stock Holding History

Marshall Wace’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,658	Closed	-$616K	–	3384
2026 Q1	$616K	Buy	+25,658	New	+$669K	﹤0.01%	2355
2025 Q4	–	Sell	-32,051	Closed	-$319K	–	3150
2025 Q3	$319K	Sell	32,051 -24,091	-43%	-$272K	﹤0.01%	2405
2025 Q2	$509K	Buy	+56,142	New	+$534K	﹤0.01%	2137
2023 Q2	–	Sell	-43,031	Closed	-$593K	–	2642
2023 Q1	$593K	Buy	43,031 +528	+1%	+$8.38K	﹤0.01%	2029
2022 Q4	$646K	Sell	42,503 -34,420	-45%	-$394K	﹤0.01%	2268
2022 Q3	$702K	Sell	76,923 -12,813	-14%	-$119K	﹤0.01%	2580
2022 Q2	$760K	Buy	89,736 +68,831	+329%	+$789K	﹤0.01%	2593
2022 Q1	$410K	Buy	20,905 +3,186	+18%	+$64.4K	﹤0.01%	2859
2021 Q4	$431K	Buy	+17,719	New	+$593K	﹤0.01%	2878

Other funds holding GLSI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's GLSI Position: Q2 2026 in Review

Marshall Wace sold out of Greenwich LifeSciences (GLSI) in Q2 2026, closing a stake of 25,658 shares — an estimated $616K sold.

Marshall Wace first reported a position in GLSI in Q4 2021 and held it in 9 quarters. The position peaked at $760K in Q2 2022. 58 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

Marshall Wace reported no remaining Greenwich LifeSciences position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 25,658 Greenwich LifeSciences shares in Q2 2026, an estimated $616K.
Marshall Wace first reported a position in Greenwich LifeSciences in Q4 2021 and held it in 9 quarters.
Marshall Wace's Greenwich LifeSciences position peaked at $760K in Q2 2022.
58 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.